DeepMind is leveraging artificial intelligence to address deadly parasitic diseases like Chagas and Leishmaniasis. The collaboration with the Drugs for Neglected Diseases initiative aims to develop effective treatments for these diseases affecting millions in the developing world. DeepMind's AlphaFold program has revolutionized protein structure mapping, achieving results in days that previously took years.
The focus on neglected diseases highlights the potential of AI to fill critical gaps in medical research. Existing treatments for these diseases are often outdated and ineffective, making the need for innovative solutions urgent. The partnership aims to discover new, orally-administered drugs that could significantly improve patient outcomes.
• DeepMind's AI predicts protein structures, aiding drug discovery for neglected diseases.
• Collaboration with DNDI aims to develop new treatments for Chagas and Leishmaniasis.
AlphaFold's ability to accurately model protein structures in days is crucial for accelerating drug discovery.
Understanding protein structures is essential for developing effective treatments for various diseases.
DeepMind's work on AlphaFold is pivotal in advancing biological research and drug discovery.
DNDI's collaboration with DeepMind aims to address the urgent need for effective therapies for diseases like Chagas and Leishmaniasis.
Pharmaceutical Technology on MSN.com 11month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.